Demonstrating real-world value is critical for securing pricing and market access, but bridging the gap between clinical trial efficacy and real-world outcomes can be complex, particularly under HTA scrutiny. Download our case study to learn how advanced modelling and real-world evidence can quantify treatment impact, support pricing negotiations, and drive commercial success.
What You’ll Learn
In this case study, you’ll discover how a pharmaceutical organization:
Combined real-world data, clinical trials, and external evidence into a unified modelling framework
Simulated long-term cardiovascular outcomes across diverse patient populations
Validated predictive models against observed real-world data
Quantified treatment impact using metrics such as event reduction and number needed to treat (NNT)
